# Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules

> **NCT03509883** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 94 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Drug: Apixaban sprinkle capsules
- **DRUG:** Experimental: Apixaban tablets followed by apixaban sprinkle capsules

## Key facts

- **NCT ID:** NCT03509883
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-26
- **Primary completion:** 2018-06-15
- **Final completion:** 2018-06-15
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2020-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03509883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03509883, "Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03509883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*